We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Appellate Reversal on OxyContin Suggests Shift on Inequitable Conduct
Appellate Reversal on OxyContin Suggests Shift on Inequitable Conduct
February 7, 2006
An appeals court has asked a lower court to review its ruling that Purdue Pharma’s patents on the painkiller OxyContin are not enforceable due to inequitable conduct — a possible signal that the appellate court is exercising more caution when reviewing inequitable conduct judgments, one patent attorney told Generic Line.